Enhancing knowledge:
the impact of experience and information

Hedyeh Hedayati

Faculty of Health Sciences
School of Medicine
The University of Adelaide
AUSTRALIA

December 2010


Declaration of Originality

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Hedyeh Hedayati, and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Hedyeh Hedayati
Acknowledgements

There are so many wonderful people who, somehow, contributed to the completion of this thesis, or who have helped and supported me in my endeavour to complete my studies. First and foremost, I would like to thank my wonderful supervisors Prof Ian Olver and Dr Hayley Whitford for giving me the opportunity to conduct this research and for their mentorship and guidance throughout my study. Over the years, they have taught me more than I thought imaginable since I first started. Their optimism and encouragement at all times helped me to stay positive and gave me a new found level of confidence in my career. Most importantly, though, I have been honoured to meet two amazing people whom I will value for life.

A special thank you to all of oncologists, nurses, and clinical trial coordinators at each of the sites I visited to carry out this project. Their enthusiasm for my research was much appreciated and their assistance was pivotal to successful recruitment of patients within the desired time frame.

A big thanks to all of the inspiring men and women who participated in my research. Without their support, this thesis would not be possible. Their time and effort in taking part in this research was invaluable and each one of them has taught me valuable lessons.

Last but not least, a huge thank you to my mum, dad and loving husband who supported me immensely and without their encouragement, sacrifices and patience I would not have been able to complete my studies. They have truly gone beyond the call of duty and I promise that this is the last degree that I would do! Thanks, also, to my amazing family and friends who have always showed interest in my study and who are proud of my achievements.
Abstract

Background

The last two to three decades has seen a shift towards patients taking a more active role in treatment decision making. One way of enabling patients to give true informed consent prior to medical treatment is to give them adequate information from which to make a reasonable decision. Research highlights that lack of knowledge or poor recall of information may result in negative consequences for the patient. A plethora of studies have been conducted on improving the type and manner in which this information is given to ultimately improve patient knowledge. Assuming there is a limit to how much information can be imparted prior to treatment, the main purpose of this research was to assess the impact that the experience of treatment in addition to the standard pre-treatment information has on patients’ eventual knowledge of chemotherapy treatment information, a unique area of research.

Methods

Part One: A literature review was conducted to determine all possible tools and methods that have been implemented for development of an improved consent process, including their effectiveness and their success in improving patient knowledge of the information given. A large number of studies were identified in assessing the effectiveness of a variety of interventions, in different populations. The main finding of this review suggests that although some of these tools may be beneficial at improving patient knowledge of the information given, patient recall was still poor. Furthermore, a majority of these studies were found to be methodologically flawed, have limited external validity, and were often conducted on small samples questioning reliability of results. Therefore, considering these limitations and the potential cost in implementing such interventions, it is believed that alternative research is necessary. Therefore, a novel area of research would be to assess the impact of treatment experience on patient knowledge of the standard pre-treatment consent information given.
Part Two: A second literature review was conducted to identify studies assessing the impact of patient experience with surgical or non-surgical treatment and its effect on patient knowledge of the informed consent information. Overall, the evidence suggested that despite having experienced treatment, a high proportion of patients still did not recall or recognise aspects of the procedure they undertook. However, scarce data indicated that further research was necessary especially in different patient populations.

Part Three: Gaps identified in part two aided the design of a longitudinal study to assess whether patient knowledge improves when the experience of chemotherapy is added to the standard pre-treatment information used for informed consent. The assessment of knowledge was based on the information given to patients on their information sheet and consent form. Some factors that may be associated with patient knowledge of treatment information given were identified from the literature reviews, either as not being, or scarcely being evaluated. Therefore, the level of patient satisfaction, trust for the physician, and social support were chosen to be measured and their changes over the chemotherapy treatment period were determined. Lastly, particular demographic or psycho-social variables were assessed as predictors of knowledge of pre-treatment information given. Seventy one consecutive men and women due to receive adjuvant chemotherapy treatment for breast or colorectal cancer participated in the study. Eligible patients who consented were visited to complete structured questionnaires at three time points.

Part Four: Six women with breast cancer agreed to participate in the in-depth qualitative interview regarding information given at the time of consent. This additional study was conducted to help triangulate findings from the longitudinal study and provide a richness of responses regarding the topics of interest.

Results

Patient knowledge of the number, name and potential side effects of chemotherapy drugs were evaluated and found to vary greatly. First, patient knowledge of the number of drugs given for chemotherapy was found to be the most highly recalled aspect of consent information
(ranging from 59.6% correct at Time 1 to 68.4% correct at Time 2) although experience over the three time points showed no significant increase in knowledge (p = .33). Second, patient knowledge of the names of drugs given, showed a significant increase over the course of chemotherapy (p = .01) although the highest proportion of correct recall was still low at only 26.3% at Time 3. Finally, an analysis of patient knowledge of chemotherapy side effects also found participants did not have significantly increased knowledge of potential side effects despite experience (p = .52) with the highest proportion of correct recall being 21.1% at Time 2.

Patient satisfaction significantly reduced over time (p = .04) although satisfaction remained moderate-to-high. The same result was found for social support with experience (p = .02). However, although trust remained high across all three time points, there was a non-significant worsening trend over the course of chemotherapy (p = .61). A number of predictors appeared to correlate with variables assessing patient knowledge of the information given. A regression model was found to be significant for the knowledge of the number of drugs \( \chi^2(8, 70) = 30.72, p = .000 \) with predictors accounting for 47.8% of the variance. The model for the name of drugs received was also significant \( \chi^2(5, 70) = 12.61, p = .03 \) with predictors accounting for 32.4% of the variance. Being female and being a private patient were found to be significant, individual predictors of knowledge of the name of drugs. However, no other predictors in the two models were strong enough to be individually significant. The patient’s age and the extent that they read the information given were the only factors found to be associated with all three measures of knowledge. The most prominent themes of the qualitative analysis included patients having a high level of trust for their physician and that the consent information form given was seen, by patients, as a reinforcement tool which they could refer to if needed.

**Conclusion**

The experience of chemotherapy treatment in addition to the standard pre-treatment information initially given to patients at consent does not appear to be sufficient at improving patient knowledge of chemotherapy. However findings suggest that different components of
the consent process are predicted by different variables. People differ in their ability to understand information, and have different circumstances and priorities that can influence their memory and interpretations. This leads to recognition of the complexity in improving the consent process and suggests that an individualised or multi-faceted approach is necessary.
# Table of contents

**Declaration of Originality** ................................................................. ii

**Acknowledgements** ........................................................................ iii

**Abstract** ................................................................................................. iv
- Background ........................................................................................ iv
- Methods .............................................................................................. iv
- Results .................................................................................................. v
- Conclusion ........................................................................................... vi

**Table of contents** ................................................................................... viii

**List of tables** .......................................................................................... xi

**List of figures** ........................................................................................ xi

**Chapter 1: Introduction** ................................................................. 1
- Setting the scene .................................................................................. 1
- Purpose of the thesis ........................................................................... 5
- Informed consent ................................................................................. 8
- Informed consent: constraints ............................................................ 20

**Chapter 2: Cancer and its medical context** ....................................... 25
- Definition of cancer ............................................................................ 25
- Breast cancer ....................................................................................... 26
- Colorectal cancer ................................................................................ 29
- Prevention, detection, and treatment strategies .................................... 31
- Cancer treatment ................................................................................ 33
- Systemic adjuvant therapies ............................................................... 34
- Summary ............................................................................................... 40

**Chapter 3: Literature review One** ..................................................... 41
- Methods .............................................................................................. 42
- Results ................................................................................................. 47
- Discussion ........................................................................................... 136
- Summary of the limitations ............................................................... 142
- Implications for future studies .......................................................... 143
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Literature Review Two</td>
<td>145</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>145</td>
</tr>
<tr>
<td></td>
<td>Methods</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>Results</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td>175</td>
</tr>
<tr>
<td>5</td>
<td>Predictors of patient knowledge of the information given</td>
<td>178</td>
</tr>
<tr>
<td></td>
<td>Satisfaction and novel predictors in the current research</td>
<td>182</td>
</tr>
<tr>
<td>6</td>
<td>Rationale for the Research Design</td>
<td>193</td>
</tr>
<tr>
<td></td>
<td>Phase one of the research</td>
<td>194</td>
</tr>
<tr>
<td></td>
<td>Phase two of the research</td>
<td>199</td>
</tr>
<tr>
<td>7</td>
<td>Quantitative Longitudinal Study: Enhancing knowledge of patients: the impact of experience and information</td>
<td>204</td>
</tr>
<tr>
<td></td>
<td>Study Research Questions</td>
<td>205</td>
</tr>
<tr>
<td></td>
<td>Methods</td>
<td>206</td>
</tr>
<tr>
<td></td>
<td>Statistical analysis</td>
<td>213</td>
</tr>
<tr>
<td></td>
<td>Results</td>
<td>215</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td>240</td>
</tr>
<tr>
<td>8</td>
<td>Qualitative study</td>
<td>246</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>246</td>
</tr>
<tr>
<td></td>
<td>Method</td>
<td>247</td>
</tr>
<tr>
<td></td>
<td>Qualitative analysis</td>
<td>248</td>
</tr>
<tr>
<td></td>
<td>Results</td>
<td>250</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td>264</td>
</tr>
<tr>
<td></td>
<td>Limitations of the study</td>
<td>267</td>
</tr>
<tr>
<td></td>
<td>Conclusion</td>
<td>269</td>
</tr>
<tr>
<td>9</td>
<td>General discussion</td>
<td>270</td>
</tr>
<tr>
<td></td>
<td>Summary of findings</td>
<td>272</td>
</tr>
<tr>
<td></td>
<td>Conclusion</td>
<td>292</td>
</tr>
<tr>
<td></td>
<td>Limitations of the studies</td>
<td>293</td>
</tr>
<tr>
<td></td>
<td>Implications for future studies</td>
<td>297</td>
</tr>
<tr>
<td>References</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td></td>
<td>Appendix A   The Nuremberg Code (Nuremberg Code, 1949)</td>
<td>315</td>
</tr>
<tr>
<td></td>
<td>Appendix B   Demographic data form</td>
<td>316</td>
</tr>
<tr>
<td></td>
<td>Appendix C   Quantitative patient questionnaire used</td>
<td>318</td>
</tr>
</tbody>
</table>
Appendix D  Template of questionnaire used for semi-structured interviews .................. 321
Appendix E  Bi-variate correlations of longitudinal study variables ............................. 325
Appendix F  Informed consent form template ............................................................ 327
Appendix G  Patient information sheet ..................................................................... 328
Appendix H  Complaints form ................................................................................ 329
List of tables

Table 1: Adjuvant treatment benefits for breast cancer patients 34
Table 2: Chemotherapy taken by patients in the study 35
Table 3: Frequency and severity of short-term side effects of common chemotherapy regimens 37
Table 4: Systematic reviews of interventions assessing changes in patient outcomes published between 1999 and 2009 44
Table 5: Study profiles of included studies 149
Table 6: Demographic characteristics of the study sample 218
Table 7: Clinical characteristics of the study sample 218
Table 8: Chemotherapy taken by patients in the study 219
Table 9: Patient sources of information 220
Table 10: Perceived patient reading and understanding of information content 220
Table 11: Help with reading information and decision making 221
Table 12: Descriptive statistics on psycho-social variables measured 222
Table 13: Patient knowledge of the number of chemotherapy drugs from Time 1 to Time 3 223
Table 14: Patient knowledge of the chemotherapy drug names from Time 1 to Time 3 225
Table 15: Changes in the knowledge of drug names between two time points 226
Table 16: List of side effects that patients had knowledge about at each time point 228
Table 17: Pairwise comparison of patient satisfaction at two time points 230
Table 18: Reliable change indices (RCIs) for total patient satisfaction with the information given 231
Table 19: Pairwise comparison of social support of patients at two time points 234
Table 20: Reliable change indices (RCIs) for social support 234
Table 21: Demographic and psycho-social correlates of knowledge of information 235
Table 22: Logistic regression model describing predictors of knowledge of the number of drugs received 237
Table 23: Logistic regression model describing predictors of knowledge of the name of drugs 238
Table 24: Standard multiple regression model of predictors of recall of chemotherapy side effects 239
List of figures

Figure 1: Flow diagram detailing the process of informed consent for medical treatment __________ 10
Figure 2: Breast cancer mortality in females, Australia 1990-2004 ____________________________ 27
Figure 3: Relative survival proportions of females with breast cancer, Australia 1982-1986 to 1998-2002 ___________________________________________________________ 28
Figure 4: Diagram illustrating the colon and rectum ____________________________________________ 29
Figure 5: Age-standardised incidence and mortality rates for colorectal cancer, Australia _______ 30
Figure 6: Proportion of patients who had knowledge of the number of chemotherapy drugs given over the chemotherapy course _________________________________________ 224
Figure 7: Proportion of patients who had complete knowledge of the name of chemotherapy drugs given over the chemotherapy course ________________________________________ 225
Figure 8: Percentage recollection of proportion of chemotherapy side effects ____________________ 227
Figure 9: Patient satisfaction with information over the chemotherapy course ____________________ 229
Figure 10: Mean level of patient trust with the physician over the chemotherapy treatment period ______ 232
Figure 11: Mean level of patient social support over the chemotherapy treatment period _________ 233